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A vacina tríplice bacteriana, contra difteria, tétano e pertussis, possui diversos 
efeitos adversos, principalmente relacionados ao componente pertussis. Este trabalho 
pretendeu desenvolver um fração deste componente, possibilitando a produção de uma 
vacina acelular (DTPa), mais segura. Foi utilizada a tecnologia recombinante através da 
qual uma porção do gene que codifica a toxina pertussis foi clonada por Reação em 
Cadeia da Polimerase (PCR) e expressa em Escherichia coli. As condições de indução 
otimizadas (0,1 mM IPTG, 3 horas, 37°C) levaram a um rendimento de 12 mg.L
-1 
 da 
proteína recombinante após a purificação. A identidade da proteína foi confirmada por 
Western blotting e espectrometria de massas. Desta forma, o presente trabalho 
desenvolveu uma metodologia adequada visando a produção industrial de DTPa no 
Brasil. 
 








Triple bacterial vaccine, against diphtheria, tetanus and pertussis has several adverse 
effects, mainly related to the pertussis component. This work intended to develop a fraction of 
this component, enabling the production of an acellular vaccine (DTaP), safer. It was used the 
recombinant technology through which a portion of the gene encoding pertussis toxin was 
cloned by Polymerase Chain Reaction (PCR) and expressed into Escherichia coli. The 
optimized induction conditions (0.1 mM IPTG, 3 hours, 37°C) led to a yield of 12 mg.L
-1
 of 
the recombinant protein after purification. Protein identity was confirmed by Western blotting 
and mass spectrometry. So, present work has developed a suitable methodology aiming 
industrial production of DTaP in Brazil. 
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1 PRESENTATION  
 
The Federal University of Paraná (UFPR) is the oldest educational institution conceived 
as a university in Brazil. It was originally founded in 1912 under the name University of 
Paraná. Today, demonstrates excellence in its undergraduate, specialization, master's and 
doctoral degrees that are guided by the principle of teaching, research and extension. 
The Department of Bioprocess Engineering and Biotechnology, belonging to this 
university, is composed of undergraduate and postgraduate. This latter including three main 
areas: agribusiness and biofuels, agrifood biotechnology and human and animal health. 
Within this last area of concentration, this study was conducted. In addition, the course values 
the training of professionals with skills and expertise to participate actively and 
interdisciplinary in the activities of the industrial market of biotechnology and the 
development of new products. Aiming at this objective, this work was developed in 
partnership with the Technology Institute of Parana (TECPAR). 
This Institute is a public corporation created in 1940 and linked to the Ministry of 
Science, Technology and Higher Education of Paraná and is active in research, technological 
development and innovation, offering technologic solutions to businesses and biological, 
biopharmaceuticals and medicines to the public sector. TECPAR consists of numerous 
laboratories, including the Laboratory of Bacterial Products for Human Use (LPB). This 
laboratory has been responsible over many years for the production of the Tetanus 
Monomeric Protein (PMT), an raw material used as carrier protein that is conjugated to the 
polysaccharide found in the extracellular capsule of Haemophilus influenzae type B, to obtain 
the Hib vaccine (against one type of bacterial meningitis). Currently, this 
protein/polysaccharide conjugate is used in the composition of the quadrivalent vaccine, 
which is part of mandatory childhood immunization schedule, allowing that with one single 
dose children are protected against tetanus, diphtheria, pertussis and meningitis. 
Among the branches that the institute works, biopharmaceuticals production is one of 
the research areas that demand improvement, especially regarding the development of new 
products and improvement and creation of new methodologies applicable to production lines. 
Therefore, this project was developed with the purpose of bringing the Institute, Federal 
University of Paraná and Brazil technological autonomy earning in the development of 






2 BIBLIOGRAPHIC REVIEW 
 
2.1 Bordetella pertussis 
 
2.1.1 Disease and epidemiology 
 
Pertussis, also known as whooping cough, is a disease of the respiratory tract that 
affects humans of all ages but has the great morbidity and mortality in young children 
especially in babies less than 1 year of age. This disease occurs due to infection by Bordetella 
pertussis, which releases a number of virulence factors, including pertussis toxin (PT), 
filamentous hemagglutinin (FHA), pertactin and fimbriae. (LEE et al., 2002; CDC, 2012). 
The main symptoms of this disease are violent coughing which often makes it hard to breathe. 
(CDC, 2012) 
This disease is endemic and presents cycles of three to five years, and, nowadays ranks 
fifth among the vaccine-preventable diseases in children under five. (WHO, 2011). Since 
2010, it has been observed a global trend of increasing number of cases of pertussis, with 
reports in California and elsewhere in the Americas.  
Even with high vaccine coverage - vaccination was responsible to avoid 37 million 
cases of illness and 587,000 deaths in 2002 (WHO, 2007) - the fall of immunity 5-10 years 
after the last vaccine dose leaves susceptible adolescents and young adults, mainly due to 
decreased protective antibody titer (BRICKS, 2007). This reduction of immunity among 
adults may be related to the reduced circulation of B. pertussis in vaccinated populations as 
well, which causes less frequent exposure to antigens, and thus, less strengthening of natural 
immunity. (CAGNEY et al., 2008). This fact can be considered serious because some studies 
showed an increased risk of complications from the disease with age, including 
hospitalizations for pneumonia and sinusitis. (ISKEDJIAN et al., 2004). Moreover, 
adolescents and adults may serve as reservoirs for pertussis and often are the source of 
infection for children, beginning the cycle of transmission to newborns and infants not yet 
immunized, and the disease remains endemic. (LEE et al., 2004). 
 
2.1.2 Pertussis toxin (PT) 
 
Pertussis toxin (PT) is one of the most complex soluble bacterial proteins. (LOCHT, 




subunits, S1, S2, S3, S4 and S5. S1 subunit catalyzes the ADP-ribosylation of G proteins in 
target cells of mammals, while the subunits S2 to S5 (called oligomer B) are responsible for 
the binding of S1 to these cells. The ADP-ribosyltransferase enzymatic activity is associated 
with the domain located in the 180 N-terminal amino acids of S1 (termed C180), while the 
rest of this subunit is involved in G protein binding and interaction with the oligomer B. 
(KAMACHI; ARAKAWA, 2004) 
Besides the enzymatic activity, mainly due to Arg9, Arg13 and Glu129 residues 
(PIZZA et al., 1989), subunit S1 is also recognized as the immunogenic portion of pertussis 
toxin once it promotes maturation of dendritic cells. These cells are responsible for activation 
of antigen-specific T and B cells which mediate adaptive immunity against B. pertussis. 
(HOU, 2003). 
Studies have shown that this subunit expressed in Mycobacterium bovis BCG was able 
to induce protective immunity against the toxin itself and also against B. pertussis in a model 
of intracerebral challenge in mice. (NASCIMENTO et al., 2000). In addition, a DNA vaccine 





Due to the emergence of new production technologies and regulatory requirements, 
vaccine production has suffered constant and deep transformations. These new products, 
however, have high value and are causing technological dependence by developing countries 
such as Brazil (HOMMA et al., 2003), which leads to the requirement for short-term 
replacement of some vaccines, including DTP, used in the Brazilian public health system.  
 
2.2.1 Celular vaccine 
 
DTP vaccine is composed of tetanus toxoid (TT), diphtheria toxoid (DT) and a 
detoxified bacterial suspension of Bordetella pertussis (PRESTES, 2008). This vaccine has 
been shown to be effective with regard to immunization against pertussis, however, several 
adverse effects are related to this vaccine component. Among these effects can be 
included,local effects such as redness and swelling and systemic effects such as fever, 




effects are exacerbated with age and therefore the last dose of vaccine is given to five or six 
years of age.  
 
2.2.2 Acelular vaccine 
 
Therefore, in recent decades many groups started to study the possibility of producing a 
DTaP vaccine, containing only purified antigens of B. pertussis. A literature review conducted 
by Keitel (1999) showed that these acellular vaccines have been well tolerated and highly 
immunogenic in adolescents and adults. These vaccines with an antigenic content more than 
50% lower than the formulations for children, and reduced adverse effects, demonstrated an 
estimated efficacy of 92% in a study among American teenagers (LEE et al., 2004). 
Initially, the approach for production of this vaccine was bacterial culture and 
subsequent purification of some proteins recognized as being immunogenic. The major 
disadvantage of this procedure is that purification of components cause a low yield, since only 
that fraction of the cell is exploited for vaccine production. Studies have shown that only 1 
dose of acellular vaccine can be produced from the same fermentation broth volume that 
would produce 10-20 doses of whole cell vaccine (HIGASHI et al., 2009). In addition, the 
vaccine generally has low immunogenicity due to chemical detoxification process by which 
must pass (PIZZA et al., 1989). 
Today, there are several vaccines on the market that allow vaccination of adult and 
young babies’ population (Annex I). However, these vaccines are produced by multinationals 
and too expensive to be acquired by the national health system of Brazil.  
  
2.2.3 New strategies 
 
Thus, current proposals for the production of DTaP consist in the use of recombinant 
technology that can be accomplished in two main ways. The first, already analyzed in the 
review of Loosmore and coworkers (1991), consists on the mutation of Bordetella pertussis to 
change certain amino acids in the S1 subunit of the toxin, responsible for toxicity thereof. The 
second, most studied currently, is the overexpression of components in microbial cells. 
Burnette and coworkers (1988) have performed the cloning of all subunits of pertussis 
toxin in Escherichia coli in order to identify key functional sites and map epitopes to obtain 
candidates for an acellular vaccine. Furthermore, cloning attempts aimed not only at  the 




already been performed in microorganisms such as Bacillus subtilis (OLANDER et al., 1991), 
Pichia pastoris, Saccharomyces cerevisiae (ROMANOS et al., 1991), Bacillus brevis 
(KOZUKA et al., 1996), besides insect cells (XU et al., 2011). 
The advantage of using these organisms is especially the low cost of the process, mainly 
due to the high yield of protein (KOZUKA et al., 1996), and greater ease of purification. 
Furthermore, the recombinant production presents the advantage of eliminating the step of 
detoxification of the protein. (RAPPUOLI et al., 1992). 
 
2.3 Cloning strategy 
 
2.3.1 Escherichia coli 
 
Escherichia coli, being one of the most known and utilized organisms for heterologous 
protein expression, is always the first option when intending to begin a cloning procedure. 
Specially because this bacterium offers a rapid and economic medium for production of 
recombinant proteins, and these advantages, combined with biochemical and genetical 
knowledge of this microorganism, have allowed its utilization for production of many 
molecules as insulin and bovine growth hormone.  
However, some difficulties are found in the utilization of E. coli for immunogenic 
proteins production, mainly related to the correct folding of the protein that is directly 
connected to its antigenic properties. Another disadvantage of the therapeutical use of 
recombinant proteins produced in E. coli is the accumulation of lipopolysaccharide (LPS), 
generally designated endotoxin, which is pirogenic in humans and other mammals. Therefore, 
proteins need to go through a special purification process for become free of these endotoxins. 
(TERPE, 2006) Nevertheless, due to the many advantages that this system offers, it is 
indicated to test it in the first step.  
 
2.3.2 pAE vector 
 
The vector used in this work is the noncommercial vector pAE, kindly provided by 
Professor Odir Dellagostin (UFPel). This vector has several advantageous features, as: 
replication origin in E. coli, multiple cloning site, ampicillin resistance, strong promoter of 
phage T7, possibility of IPTG induction and inclusion of polyhistidine tail to the cloned 






3.1 General objective 
 
Develop a reagent with the potential for use in acellular DTP vaccine (DTaP) made 
from a recombinant antigen produced by cloning and expression of an immunogenic protein 
of Bordetella pertussis. 
 
3.2 Specific aims 
 
 Cultive a strain of Bordetella pertussis to obtain biomass for DNA extraction; 
 Cloning a portion of S1 subunit of pertussis toxin by PCR from the extracted DNA 
eliminating the enzymatic activity and, thus, the potencial pathogenicity of the molecule; 
 Integrate the gene fragment in a plasmid that can be inserted and expressed in 
Escherichia coli; 
 Execute the induction of protein expression and purification; 




















4 MATERIAL AND METHODS 
 
4.1 Reactivation of strain, cultivation and inactivation of B. pertussis 
 
The freeze-dried content of an ampoule of B. pertussis strain 137 (BP/T/01/99) obtained 
from TECPAR was homogenized with sterile saline solution (NaCl 0.9%), inoculated in an 
Erlenmeyer flask containing 50 mL of Stainer-Scholte medium (STAINER; SCHOLTE, 1971) 
(Annex II), and incubated on a shaker at 37°C and 150 rpm for 48 hours. Gram staining was 
performed to confirm identity and purity of culture. Furthermore, the strain was transferred to 
plates containing solid medium Charcoal Agar Base with Niacin (Annex II) and incubated at 
37°C for 5 days, then, stored at 4°C.  
Liquid cultures were distributed in 50 mL centrifuge tubes, inactivated in water bath at 
60°C for 30 minutes and then centrifuged at 5000 xg for 20 minutes at 4°C for cell recovery. 
Pellets were stored at 4°C. (GUPTA et al., 1988) 
All these procedures were performed in a biosecurity area in TECPAR.  
 
4.2 Extraction and quantification of the DNA of B. pertussis 
 
Pellet of one of the centrifuge tubes was used for DNA extraction that was developed 
combining freeze-thaw and phenol/cloroform/isoamil alcohol techniques (Annex III). It was 
read sample absorbance at 260 nm and an aliquot was applied to a 0.8% agarose gel and run at 
80 V for 1 hour. Then, it was colored with Ethidium Bromide to verify the quality of DNA. 
 
4.3 Primers design 
 
The analysis needed for primers design intending properly amplification of the desired 
region of DNA and construction of the resulting plasmid in silico (Annex IV) was performed 
using the software Vector NTI (Invitrogen®).  
ptxA gene sequence, encoding the S1 subunit of pertussis toxin was obtained from 
GenBank (GeneID: 2665068, locus tag BP3783) (Annex V). Aiming the directional cloning 
of amplicons into the expression plasmid, restriction sites for the enzymes BamHI and HindIII 
were introduced in forward and reverse primers, respectively. The region selected for 




eliminating the potential pathogenicity of the molecule. Including the nucleotides inserted by 
the primers, the fragment size expected after PCR reaction is 698 bp. 
 
4.4 Amplification of the gene of interest by PCR 
 
PCR reaction was prepared following the GoTaq® Flexi DNA Polymerase (Promega) 
manufacturer’s protocol, using 1 µL of 10 ng/µL DNA template for each 50 µL of reaction 
mix. The conditions of PCR were: 95ºC for 5 min (initial denaturation), 30 cycles of: 95ºC for 
30s (denaturation), 55 ºC for 30s (annealing), 72ºC for 1 min (extension); 72ºC for 5 min 
(final extension). Efficacy of amplification was determined by running samples on an agarose 
gel 1.0% at 80 V for 1 hour. 
 
4.5 Preparation of vector and gene for ligation 
 
Both the gene obtained by PCR (after purification with GFX
TM
 PCR DNA and Gel 
Band Purification kit (GE Healthcare)) and the vector – pAE – were subsequently digested 
with restriction enzymes BamHI (ThermoScientific) and HindIII (Promega) according to the 
manufacturer’s protocol (Annex VI). Their concentrations were determined by 
spectrophotometry at 260 nm and the efficacy of digestion was determined in agarose gel 
1.0%. The ligation reaction was executed with T4 DNA ligase (Promega) overnight at 4 ºC 
following the manufacturer’s protocol. (Annex VII) 
 
4.6 Transformation of E. coli DH5α for plasmid replication 
 
The plasmids obtained were used to transform E. coli DH5α by heat shock (Annex VIII) 
for replication and verification of the success of ligation. In addition, a negative control was 
performed with pAE. The transformations were spread on Petri dishes containing LB medium 
supplemented with 100 mg/L of ampicillin (once the vector has the gene of resistance to this 
antibiotic) and incubated overnight at 37°C. The colonies observed on the plate were 
subjected to screening with phenol/chloroform to confirm the presence of the plasmid. 3 
colonies were selected, which were inoculated in 5 mL LB medium with ampicillin, incubated 
overnight on rotatory shaker at 180 rpm and 37°C and used for the extraction of plasmid with 




To confirm the presence of inserts in the plasmids extracted, was performed a double 
digestion with the same enzymes and verified on an agarose gel 1.0%  
 
4.7 Transformation of E. coli BL21 pLysS and induction of recombinant protein 
expression 
 
The selected plasmid was utilized for transforming E. coli Bl21 pLysS expression cells. 
Cells transformed by heat shock (Annex VIII) were inoculated in LB medium containing 
ampicillin and 25 mg/L of chloramphenicol (to maintain the plasmid and pLysS) and 
incubated on rotatory shaker at 180 rpm overnight at 37°C. Cells without transformation also 
incubated in non-selective LB broth were utilized as negative control.  
1 mL of this pre-inoculum was inoculated in 10 mL of LB medium with the same 
antibiotics and incubated on a rotatory shaker at 37°C and 180 rpm until the culture reaches 
optical density (OD) of 0.6 at 600nm. Then, induction of expression was performed with 
IPTG 0.3 mM for 3 hours. The confirmation of the recombinant protein expression was 
performed by electrophoresis SDS-PAGE on a 10% gel. (Annex IX).  
 
4.8 Pre-inoculum production 
 
The production of pre-inoculum has been performed in order to prevent new 
transformation would be required at each start of fermentation. So, transformed cells were 
stored at -80°C being stable for long periods.  
For this purpose, 25 mL of transformed culture with OD of 0.5 was centrifuged at 3000 
xg for 10 minutes at 4°C to recover the cells. The pellet obtained was resuspended in 2.5 mL 
of LB broth with antibiotics and 2.5 mL of sterile glycerol. The suspension was homogenized 
by vortexing and kept on ice while 200 µL aliquots were distributed into microcentrifuge 
tubes and stored at -80°C. 
 
4.9 Solubility test to verify the presence of the protein in the supernatant or in 
inclusion bodies 
 
1 mL of the pre-inoculum (see item 4.7) was used to inoculate 9 mL of LB broth with 
antibiotics and incubated overnight at 37°C and 150 rpm. Then, the culture was used to 




until reach OD of approximately 0.8. IPTG was added to a final concentration of 0.3 mM and 
induction proceeded for 3 hours. The final culture was centrifuged at 7000 xg and 4°C for 15 
min, the pellet obtained was washed with PBS (Annex X), centrifuged again under the same 
conditions and resuspended in 10 mL resuspension buffer. 4 pulses of sonication of 20s with 
the same time interval were performed. Then, another centrifugation at 15000 xg and 4°C for 
10 min was performed to precipitate inclusion bodies. The supernatant was stored at 4°C and 
called soluble fraction. The pellet was resuspended in 10 mL solubilization buffer and was 
carried out a new cycle of sonication and centrifugation. The supernatant obtained was called 
insoluble fraction. Both fractions were applied to 10% polyacrylamide gel and submitted to 
Western Blotting analysis with anti-his6 antibody (Annex XI). 
 
4.10 Cell growth and protein production kinetics 
 
During fermentation process (see item 4.9) every hour were collected aliquots of 2 mL 
for prior verification of the influence of the induction time in cell growth and protein 
production. These fractions were centrifuged for 5 min at 11000 xg. The pellet obtained was 
resuspended in 200 µL of solubilization buffer (see item 4.9), passed through a cycle of four 
sonication pulses of 5s with the same time interval and again centrifuged under the same 
conditions. The supernatant was stored for further analysis in SDS-PAGE. To determine de 
growth rate (μ) at the different phases of the culture, it was used the following equation:  
μ = (lnxt – lnx0) / (t – t0); where, xt and x0 are the cell concentrations at times t and t0, 
respectively. Cell concentrations were determined multiplying OD value by 0.35, once Lima 
(2004) described that for recombinant E. coli cultures, 1 U of absorbance at 600 nm 
corresponds to a cell concentration of 0.35 g/L, on a dry basis. 
 
4.11 Optimization of expression 
 
The most important factors when dealing with expression of recombinant proteins are 
the concentration of inducer (IPTG), the time and temperature of induction. To study these 
factors was carried out an experimental design of the type fractional factorial 3
(3-1)
 with three 
replicates at the center point. This type of design allows determining the statistical 
significance of each factor studied for the process. The levels studied of induction time were 




were set as commonly used for recombinant protein expression in E. coli. 
(PAPANEOPHYTOU; KONTOPIDIS, 2012) (Table 1) 
 
Table 1 - Factors and levels studied on expression optimization. 
Factors/Levels -1 0 1 
Temperature (°C) 25 31 37 
IPTG (mM) 0.1 0.5 0.9 
Induction time (h) 2 3 4 
 
One pre-inoculum of the cell bank (item 4.8) was used to inoculate 10 mL of LB 
medium with antibiotics for each experiment, and after an overnight growth, this culture was 
inoculated into 100 mL new LB broth with antibiotics.  Fermentation and sampling was 
performed as described in 4.9. Samples were run on polyacrylamide gel at 10%. Gel image 
analysis was performed using the Image J software (NIH). The results were analyzed using 
the software Statistica 5.0.  
 
4.12 Large-scale induction 
 
Production of the recombinant protein for purification was performed in a final volume 
of 1 L following the same culture conditions as described on item 4.9. The cycles of 
sonication/centrifugation were performed until it was not observed any bacterial mass in 
suspension. This sample was named clarified fraction. 
 
4.13 Protein purification 
 
Purification was performed by affinity chromatography using a pre-packed column 
HisTrap FF 5 mL from GE Healthcare. These columns are filled with nickel resin which has 
affinity for polyhistidine tails present in the recombinant protein. 25 mL of the clarified 
fraction were injected in the column after balance with binding buffer. Elution was performed 
using imidazole, compound that has greater affinity for nickel then polyhistidine tails, thus 
being able to disconnect histidine from the resin. All buffers contained urea to ensure that 
inclusion bodies would be solubilized. Purification was performed on automated system 
ÄKTApurifier GE Healthcare. The protocols were adapted from those recommended by the 




After each chromatographic step, 150 µL of each fraction were aliquoted and stored at - 
80°C for subsequent dosage of total protein content (BRADFORD, 1976) and protein profile 
electrophoresis analysis. 
 
4.14 Protein identification 
 
4.14.1 DNA sequencing 
 
Both forward and reverse strains of the insert were sequenced in the ABI-PRISM 3100 
Genetic Analyzer (Applied Biosystems). Results obtained were compared with sequences of 
BLAST (NCBI) database to confirm that the correct fragment has been amplified.  
 
4.14.2 Mass spectrometry 
 
A protein band obtained by the SDS-PAGE was digested with trypsin (Promega) at 
37°C for 24 hours. The sample was hydrolyzed in a mixed solution HCCA matrix-α-cyano-4-
hydroxycinnamic acid ‖. The mass spectrum was obtained using the spectrophotometer 
MALDI-TOF/TOF Autoflex II (Bruker Daltonics, Germany). Some signals present in the 
mass spectrum MS were fragmented in mode MS/MS. Peaks were analysed with the 




5 RESULTS AND DISCUSSION 
 
5.1 Extraction of the DNA of Bordetella pertussis and amplification of the gene 
of interest by PCR 
 
The average concentration of the DNA samples determined by spectrophotometry at 
260 nm was approximately 3000 µg/mL (Annex XIII). 
It was confirmed the fragment of the desired size (698 bp) and only one band in the 
sample, which evidences no nonspecific amplification (Figure 1). Furthermore, in negative 
control (NC) was not observed any band.  
 
5.2 Preparation of vector and gene for ligation 
 
Efficacy of digestion was proved, once at the pAE sample can be observed various 
bands and on pAE digested it can be observed only one band with the expected size (2822 
bp). (Figure 2) Normally, on a noncut plasmid sample, it can be seen four different bands, 
corresponding to variations in DNA folding, once not only the size but also the shape affects 
migration in electrophoresis. When plasmid is cut, it migrates as linear DNA, so, the presence 
of only one band is expected. (SAMBROOK; RUSSEL, 2001) 
On the other samples it can’t be seen any difference, once the digestion eliminates only 
a few nucleotides and then presents no significant difference on molecule size.  
 
5.3 Transformation of E. coli DH5α for plasmid replication 
 
It was observed the growth of six colonies on the plate which was seeded with a culture 
transformed with plasmid pAE-S1. After screening by electrophoresis (figure 3), it can be 
observed that four colonies (P1, P2, P3 and P4) present the same pattern of running as 
negative control samples. P5 presents plasmid without insert, when compared with pAE 
sample. P6 presents a different pattern, although the plasmid seems to be smaller than pAE. 
Even so, this difference in running can occur due to variation in plasmid folding as described 
in item 5.3. So, P6 was previously chosen for plasmid extraction. Nevertheless, plasmids from 
P4 and P5 were also extracted for comparison after double digestion and thus, confirm the 





Figure 1 – Agarose gel 0.8% of polymerase chain reaction products. 





Figure 2 – Eletrophoresis in agarose gel 1.0% of the polymerase chain reaction products digested. 
1 Kb plus = molecular weight marker; pAE = noncut vector; pAE B = vector after digestion with BamHI; 
P B = amplicon digested with BamHI; pAE B/H = vector after digestion with BamHI and HindIII; P B/H = 




Figure 3 – Screening of colonies after transformation. 
1 Kb plus = molecular weight marker; NC 1, NC 2, NC 3 = DNA extracted from 3 colonies of negative control; 
E. coli = DNA extracted from one E. coli DH5α colony; pAE = noncut vector; P1 until P6 = DNA extracted 
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5.4 Confirmation of the presence of the insert in the plasmid obtained 
 
Double digestion of the extracted plasmids confirmed the expected results (Figure 4), 
once only digestion of plasmid of the P6 colony has shown a band of 698 bp. Thus, this 




Figure 4– Double digestion of plasmid extracted from screening selected colonies. 
1 Kb plus = molecular weight marker; pAE B/H = vector after digestion with BamHI and HindIII; P4 B/H 
= plasmid digested with BamHI and HindIII; P5 B/H = plasmid digested with BamHI and HindIII; P6 B/H = 
plasmid digested with BamHI and HindIII. 
 
 
5.5 Confirmation of expression of the protein of interest 
 
In SDS-PAGE (Figure 5) can be observed a band with approximately 28 kDa 
overexpressed in the inducted sample. This confirms the expression of the recombinant 
protein, and the efficiency of IPTG in the induction of protein expression. Although, it can be 
also seen a band with less intensity corresponding to the recombinant protein in non-inducted 
ample. This can show that the system of expression control, regulated by pLysS plasmid, is 
not completely efficient. 
 
 
Figure 5 – Verification of recombinant protein expression. 
MW = molecular weight marker; NC ni = negative control before induction; NC i = negative control after 
induction; P ni = transformed cells before induction; P i = transformed cells after induction. 
kDa          MW        NC ni        NC i         P ni            P i 





























5.6 Solubility test to verify the presence of the protein in the supernatant or in 
inclusion bodies 
 
The solubility test has demonstrated the presence of the recombinant protein mainly in 
the insoluble fraction, in other words, in inclusion bodies (Figure 6) while a big part of other 
proteins are extracted in the soluble fraction. This is expected for recombinant proteins 
expressed in E. coli and this result was also obtained by Burnette (1988) that expressed 
recombinant S1 subunit of pertussis toxin at high phenotypical levels (7 to 22% of total cell 
protein content) in inclusion bodies. Choi and coworkers (2006) said that overexpressed 
proteins are often produced in the form of inclusion bodies and set several advantages in this 
fact, like: much higher levels of protein accumulation (usually greater than 25% of total 
proteins) than soluble proteins; inclusion bodies can be initially isolated in a highly purified 
and concentrated state by simple centrifugation leading to a significant decrease in 
downstream processing requirements for removing contaminating host proteins; resistance to 
proteolysis by E. coli proteases, allowing high-yield protein production. (CHOI, KEUM, 
LEE, 2006) 
Nevertheless, this result can lead to some difficulties, once the protein needs to be 
refolded to be soluble in a common saline buffer and this process is not so easy to all proteins. 
 
 
Figure 6 – Recombinant protein solubility. 
MW = molecular weight marker; NC = negative control insoluble fraction; P SF = soluble fraction of 
recombinant cells; P IF = insoluble fraction of recombinant cells. 
 
 
It was also confirmed the presence of the protein in the insoluble fraction by Western 
Blotting (Figure 7). 




















Figure 7 – Western blotting showing two fractions (soluble and insoluble). 
1 = molecular weight marker (not recognized by anti-his6); 2 = negative control insoluble fraction; 3 = soluble 
fraction of recombinant cells; 4 = insoluble fraction of recombinant cells. 
 
 
5.7 Cell growth and protein production kinetics 
 
In the kinetic analysis of cell growth of cells of E. coli BL21 pLysS, lag phase was not 
observed for cells not transformed (NC). However, to cells transformed with the recombinant 
plasmid (P), lag phase was observed until the third hour of incubation. Only after 5 hours of 
cultivation, the absorbance at 600 nm reached an average value of 0.7, and was performed 
induction with IPTG. The exponential phase was observed from the third to half of the fifth 
hour of growth. (Figures 8 and 9) Following the addition of the inducing agent, was observed 
a decrease in growth rate, which was expected since overexpression overproduction of 
heterologous protein imposes metabolic burden stress, subsequently, cell growth decreases. 
(KIM et al., 2003) 
The graphic of the natural logarithm of the cell concentration as a function of time 
represents the variation in growth rate (μ) (Figure 9). The calculated μ for each phase of the 
growth of transformed cells (P) is:  0.358 h
-1 
(lag phase), 0.626 h
-1
 (exponential phase) and 
0.215 h
-1
 (after induction). 
Cell concentration reached at the end of fermentation, both for the negative control, as 
for the transformed cells were approximately 0.42 g/L of fermentation broth. 
Analysis of protein expression in each fermentation time indicates that the maximum 
expression was achieved at the end of fermentation, 3 hours after induction and that there was 
little change in other proteins present in the sample during this time (Figure 10). As the 
fermentation was not getting any samples after this time, it is unclear, in this experiment, 
whether a longer time would be even better for protein production. 






Figure 8 – Growth kinetics of transformed (P) and non-transformed (NC) cells before and after addition of 










































































Figure 10 – Evaluation of influence of induction time in expression profile. 
MW = molecular weight marker; NC = negative control; P ni = protein profile before induction; P 1h = 
protein profile after 1 hour of induction; P 2h = protein profile after 2 hours of induction; P 3h = protein 
profile after 3 hours of induction. 
 
 
5.8 Optimization of expression 
 
The analysis of the bands intensities in SDS-PAGE gel shows the best result was 
achieved in the experiment seven (in bold), where the conditions were: 37°C, 0,1 mM of 
IPTG and 3 hours of induction (Table 2). These results were obtained for the insoluble 
fraction of culture, once in the soluble fraction was not observed the recombinant protein band 
for any condition (data now shown). 
Pareto diagram (Figure 11) of the experiment demonstrates that time of induction and 
IPTG concentration are statistic significant variables in expression of this protein, with p-
value (significance level) of 0.05 or 5%. This diagram also shows that increase of IPTG 
concentration has a negative effect on protein production, i.e., this variable must be used in 
their lower value to achieve maximum expression values. This is very important when 
thinking about industrial processes, once IPTG is an expensive addictive, and if low 
concentrations give better responses, the costs are reduced. 
The statistical significance of the model was checked and the equation coefficient (R
2
) 
calculated was 0.935, suggesting that the fitted model could explain 93.5% of total variation.  
The result obtained for the influence of IPTG concentration agree with that obtained by 
Cao and coworkers (2006) that have tested six different concentrations of this compound for 
induction of 1,3-propanediol oxidoreductase expression in E. coli and obtained the optimal 
value of 0.1 mM (the lower concentration tested).   





















Table 2 - Results of band intensities (peak area) obtained for the experimental design 3
(3-1)
 fractional factorial 
with 3 replicates of central point. 
Experiment Factors 
 Temperature IPTG Induction time Peak area 
1 -1 -1 -1 5202518 
2 -1 0 1 256607 
3 -1 1 0 5604640 
4 0 -1 1 5232104 
5 0 0 0 6442711 
6 0 1 -1 5629640 
7 1 -1 0 8103196 
8 1 0 -1 5311104 
9 1 1 1 268314 
10 (C) 0 0 0 5967518 
 
11 (C) 0 0 0 6971882 

















5.9 Protein purification 
 
SDS-PAGE of the samples acquired at purification of the clarified fraction (obtained as 
described in item 4.13) demonstrates that a prior purification could be done, but, even so, it 
has some proteins that were eluted together with the recombinant protein (Figure 13). This 
fact can be due to the low concentration of imidazole (5 mM) in the binding and washing 
buffer, once the column protocol recommends concentrations between 20 and 40 mM of this 
compound to decrease unspecific binding. Although, previous tests (data not shown) indicated 
that higher concentrations led to eluting the protein in binding and washing steps, fact that can 
also be seen in figure 12.  
 
 
Figure 12 – Samples of purification process in HisTrap FF column. 
MW = molecular weight marker; BP = sample before injection in column; NB = not-bounded proteins; W1, W2, 
W3 and W4 = fractions of column washing; E1, E2, E3, E4, E5, and E6 = eluted fractions. 
 
Other strategies can be tested to improve purification, including decreasing NaCl 
concentration in all buffers, facilitating to the protein to bind the resin and then, increasing 
imidazole concentration to avoid unspecific binding.  
Moreover, once the proteins with similar molecular weight has been yet excluded from 
the sample by the affinity chromatography, two steps of ultrafiltration with membranes of 20 
and 35 kDa,  or gel filtration chromatography could eliminate other proteins and also 
concentrate sample. It would also be useful to change buffer (to take off imidazole, urea and 
decrease salt concentration) and promote protein refolding, so it can be used for biological 
tests. Finally, the protein was eluted in 4 fractions (E2, E3, E4, and E5), and their 
concentrations, determined by Bradford analysis, in µg/mL, were, respectively: 133.73; 
328.902; 272.176 and 91.364. So, the major fractions of the recombinant protein are the 
elutions three and four. Analysis of the gel image by software Image J (Annex XIV) gave the 



















proportion of the band of recombinant protein in function of total bands of each sample, and 
they are, respectively 54.28%, 71.53%, 75.21%, 95.79%. So, in these four fractions, it can be 
estimated that the total yield of protein obtained was 16.52 mg/L of total culture and, 
considering purity, this yield is estimated on 12 mg/L. 
This result is more than 3 times higher than obtained by Buasri and coworkers (2012) 
that have constructed mutant B. pertussis strains to produce genetically inactivated pertussis 
toxin and achieved and expression of this protein of only 3.77 ± 0.53 mg/L of culture. 
Moreover, cultivation of B. pertussis requires a rich medium (see item 4.1) and, thus, is much 
more expensive than E. coli fermentation.  
Another attempt to produce and fusion protein of subunits S1 and S3 of PT and FHA in 
Streptococcus gordonii has only achieved 12 µg of protein per liter of culture (LEE et al., 
2002). Yet, the expression of S2 subunit of PT in Bacillus brevis has yielded 70 mg of protein 
per liter of culture (KOZUKA et al., 1996). 
 
5.10 Protein identification 
 
5.10.1 DNA sequencing 
 
Comparison of the nucleotide sequence obtained from the cloned gene (Annex III) with 
BLAST database resulted in 99 matches with 99% of identity and E-value of 0.0. The lower 
the E-value, or the closer it is to zero, the more "significant" the match is. These matches were 
mainly of Bordetella pertussis pertussis toxin S1 subunit (ptxA) gene, as expected. There 
were results from Bordetella parapertussis and Bordetella bronchiseptica also. (Annex XV) 
 
5.10.2 Mass spectrometry 
 
Protein identification by mass spectrometry in MALDI-TOF has returned some hits 
according to pertussis toxin S1 subunit [Bordetella pertussis], but, not with so high scores 
(data not shown). This can be due to some contaminants in the sample after purification, 
which not led the equipment to distinguish between the peaks analyzed. Even so, once DNA 
fragment has also been sequenced and confirmed the correct protein, this result also confirms 






6 CONCLUSIONS AND PERSPECTIVES 
 
By the proposed method, it was concluded that: 
- It was possible the amplification of a specific DNA fragment (containing 684 bp) of 
the S1 subunit of pertussis toxin by PCR. 
- This fragment, after digestion, insertion into specific vector and transformation into E. 
coli was able to be translated the S1 subunit of the pertussis toxin 
- This expression was confirmed by SDS-PAGE once has been obtained a protein of 
approximately 28 kDa as expected, and Western Blotting with the anti-His6 antibody that 
recognized the same protein. 
- The experimental design showed that the best conditions for inducing the expression 
of this protein have been the use of 0.1 mM IPTG lasting only 3 hours of induction at 37°C; 
although only IPTG and time were statistically significant factors.  
- Production of a bank of transformed cells for use as pre-fermentation inoculum was 
efficient; 
- The protein was expressed in insoluble form, the inclusion bodies were isolated and it 
has consisted in the first step of purification, then, this pre-purified suspension, were 
efficiently purified by affinity chromatography. 
- The sequencing of DNA fragment and identification of the expressed protein have 
confirmed the satisfactory result of all cloning step 
 
Thus, since it was succeeded in the expression of the antigen of interest, it is necessary 
to optimize purification process and check its biological activity through in vitro and in vivo 
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Diphtheria toxoid (DT) 25 Lf 15 Lf 30 U.I. 2 Lf 
Tetanus toxoid (TT) 10 Lf 5 Lf 20 U.I. 5 Lf 
Pertussis toxoid (PT) 25 μg 10 μg 25 μg 2,5 μg 
Filamentous 
hemagglutinin 
25 μg 5 μg 25 μg 5 μg 
Pertac 
tin (69 kDa) 
8 μg 3 μg - 3 μg 
Fimbriae - 5 μg - 5 μg 
AGE INDICATION 4-6 years 6 weeks – 4 
years 
2 – 13 years 4 – 64 years 
Source Johns & 
Rutter 
(2010) 




























Annex II – Bordetella pertussis culture medium composition 
 




Tris base 6,06 g 
Monosodium glutamate monohydrate 11,86 g 
Proline 0,24 g 
NaCl 2,5 g 
KH2PO4 0,5 g 
KCl 0,2 g 
MgSO4 0,126 g 
CaCl2 0,02 g 
HCl 37% 3,4 mL 
Deionized water q. s.  1 liter 
 
Solution 2:  
Component Quantity 
L-cistine 0,4 g (dissolve in a few mililiters of HCl) 
FeSO4.7H2O 0,1 g 
Ascorbic acid 0,1 g 
Niacin (nicotinic acid) 0,04 g 
Glutathione reduced 1,0 g 
Deionized water q. s. 100 mL 
 
The solution number 1 was sterilized by autoclaving. The solution number 2 was 
sterilized by filtration and added to solution 1 in the proportion of 10 mL/L. 
 
 Charcoal Agar Base with Niacin medium: 
 
Component Quantity 
Pancreatic digest of gelatina 2 g 
Beef extract 2 g 
NaCl 1 g 
Starch 2 g 
Nicotinic acid 0,0002 g 
Charcoal 0,8 g 
Agar 2,4 g 
Deionized water qsp 200 mL 
 





Annex III - DNA Extraction protocol 
 
 Resuspend pellet in 500 µL in TE buffer by repeated pipetting (10 mM Tris-HCl 
pH 8.0, 1 mM EDTA pH 8.0). 
 Perform 3 freezing and thawing cycles (-70ºC, 5’; 80-95ºC, 2’). 
 Add 0.02 volume (at least 500 µL) of lysozyme (10 mg/mL) and incubate to 
37ºC for 1 hour. 
 Add 0.01 volume of SDS 10% and 0.01 volume of proteinase K (20 mg/ml). 
Mix thoroughly and incubate 1 h at 55C. 
 Warm up to 95ºC for 10’ to denature proteinase K. Centrifuge 1000 xg, 5’. 
 Add 0.01 volume of RNase (20 mg/mL) and incubate 37ºC, 30’. 
 Add the same volume of phenol/chloroform/isoamyl alcohol (25:24:1) and 
gently mix thoroughly for 5’ and spin 12000 xg, 5’ in a microcentrifuge. 
 Remove aqueous, viscous supernatant to a fresh microcentrifuge tube, leaving 
the interface behind. Add an equal volume of phenol/chloroform/isoamyl 
alcohol, extract thoroughly, and spin in a microcentrifuge for 5 min. 
 Transfer the supernatant to a fresh tube. Add 0.1 volume sodium acetate 3M, pH 
5.2 and 2 volume ethanol (-20ºC). Gently mix thoroughly. 
 Spin 12000 xg, 30’, 4ºC. 
 Transfer the pellet to a fresh tube containing 300 µL of 70% etanol 9-20ºC). spin 
12000 xg, 15’, 4ºC . Repeat this step. 






















Annex IV – pAE vector and resultant plasmid 
 














Annex V – Nucleotide sequence of the fragment cloned and primers  
 
ptxA toxin subunit 1 [ Bordetella pertussis Tohama I ] - Gene ID: 2665068 
 
   1 atgcgttgca ctcgggcaat tcgccaaacc gcaagaacag gctggctgac gtggctggcg 
 61 attcttgccg tcacggcgcc cgtgacttcg ccggcatggg ccgacgatcc tcccgccacc 
121 gtataccgct atgactcccg cccgccggag gacgttttcc agaacggatt cacggcgtgg 
181 ggaaacaacg acaatgtgct cgaccatctg accggacgtt cctgccaggt cggcagcagc 
241 aacagcgctt tcgtctccac cagcagcagc cggcgctata ccgaggtcta tctcgaacat 
301 cgcatgcagg aagcggtcga ggccgaacgc gccggcaggg gcaccggcca cttcatcggc 
361 tacatctacg aagtccgcgc cgacaacaat ttctacggcg ccgccagctc gtacttcgaa 
421 tacgtcgaca cttatggcga caatgccggc cgtatcctcg ccggcgcgct ggccacctac 
481 cagagcgaat atctggcaca ccggcgcatt ccgcccgaaa acatccgcag ggtaacgcgg 
541 gtctatcaca acggcatcac cggcgagacc acgaccacgg agtattccaa cgctcgctac 
601 gtcagccagc agactcgcgc caatcccaac ccctacacat cgcgaaggtc cgtagcgtcg 
661 atcgtcggca cattggtgcg catggcgccg gtgataggcg cttgcatggc gcggcaggcc 
721 gaaagctccg aggccatggc agcctggtcc gaacgcgccg gcgaggcgat ggttctcgtg 
781 tactacgaaa gcatcgcgta ttcgttctag 
Underlined nucleotides are the fragment cloned.  





Underlined nucleotides are the restriction sites for BamHI (S1_for) and HindIII (S1_rev) 
 





















Ultrapure water 28 µL 
5X Buffer 5 µL 
DNA 15 µL 
BamHI 2 µL 





 PCR DNA and Gel Band Purification kit (GE Healthcare). 





Ultrapure water 22.5 µL 
5X Buffer 5 µL 
BSA 0.5 µL 
DNA 20 µL 
HindIII 2 µL 
TOTAL 50 µL 
 
2 hours at 37ºC 
Purification with GFX
TM
 PCR DNA and Gel Band Purification kit (GE Healthcare). 
Recovered in 25 µL. 
 
Annex VII – Ligation reaction 
 
 S1 pAE (negative 
control) 
Vector 5 µL 5 µL 
Insert 8 µL -------- 
 10X Buffer  2 µL 2 µL 
T4 DNA ligase 1 µL 1 µL 
Ultrapure water 4 µL 12 µL 
TOTAL 20 µL 20 µL 
 




Annex VIII – Heat shock transformation protocol 
 
Step 1: production of competent cells 
 10 isolated colonies of E. coli have to be grown in 20 mL LB medium at 37°C  
until A600= 0.5 (about 3-4h) 
 centrifuge the E. coli solution at 3000 xg at 4°C for 10 min in ice-cold sterile 
centrifugation tubes 
 suspend the cell sediment in 20 mL ice-cold 0.1 M MgCl2 solution 
 centrifuge at 3000 xg at 4°C for 10 min 
 suspend the cell sediment in 20 ml ice-cold 0.1M CaCl2 solution and incubate 
for 30 min at 4°C 
 centrifuge at 3000 xg at 4°C for 10 min 
 suspend the cell sediment in 1 ml ice-cold 0.1 M CaCl2 solution 
 add 100 µL glycerol (sterilized by autoclaving) and freeze the cell suspension at 
-80°C in 100 µL  
 
Step 2: transformation of the competent cells 
 thaw the suspension with the competent E; coli cells on ice (about 15 min) 
 add 20 µL competent E. coli cell solution to 5 ng (2 µL) plasmid DNA  
 incubate for 30 min on ice 
 incubate for 90 s at 42°C 
 incubate for 2 min on ice 
 add 200 µL LB medium 
 incubate at 37°C for 2h while agitating 
 transfer to 5 mL of selective LB medium (with the necessary antibiotics) or 
spread in Petri dishes contained the same medium 









Annex IX – SDS-PAGE  
 
 10%  resolving gel 
 1 gel (10 mL) 2 gels (15 mL) 
Purified water 4.0 mL 5.9 mL 
30% acrylamide mix 3.3 mL 5.0 mL 
1.5 M Tris (pH 8.8) 2.5 mL 3.8 mL 
10% SDS 0.1 mL 0.15 mL 
10% ammonium persulfate 0.1 mL 0.15 mL 
TEMED 0.004 mL 0.006 mL 
 
 
 5% Stacking gel 
 1 gel (2 mL) 2 gels (4 mL) 
Purified water 1.4 mL 2.7 mL 
30% acrylamide mix 0.33 mL 0.67 mL 
1.5 M Tris (pH 8.8) 0.25 mL 0.5 mL 
10% SDS 0.02 mL 0.04 mL 
10% ammonium persulfate 0.02 mL 0.04 mL 
TEMED 0.002 mL 0.004 mL 
 
 
















Annex X – Buffers composition 
 
PBS: 
137 mM Sodium chloride 
2.7 mM Potassium chloride 
10 mM Disodium hydrogen phosphate 




20 mM NaH2PO4 
pH 8.0 
 
Solubilization Buffer:  
20 mM NaH2PO4 






















Annex XI - Western Blotting protocol 
 
 After electrophoresis, note gel dimensions, mark the beginning and equilibrate the 
gel in transfer buffer (10-30 min) 
 Preparing the membrane: wet in 100% methanol (15 s), and rinse with ultrapure 
water for 15-20 s; balance in transfer buffer for at least 5 min; 
 Soak the filter paper and sponges in transfer buffer for at least 30 seconds; 
 To assemble the sandwich, follow the order: negative support, sponge, filter paper, 
gel, membrane, filter, sponge, positive support. 
 Remove bubbles between every layer of the sandwich 
 Place the sandwich in the vessel, add transfer buffer and connect the power. 
Transfer at 24 V and 4 ° C overnight. 
 Increase the voltage to 48 V and held for 1 hour. 
 Remove the membrane and rinse it with distilled water; 
 Block the membrane in blocking buffer for 1 hour with gentle agitation. 
 Incubate the membrane with anti-His (GE Healthcare) primary antibody diluted 
1:3000 in blocking buffer 
 Incubate for 1 hour at room temperature with gentle agitation 
 Wash the membrane three times for 5 minutes with wash buffer. 
 Incubate the membrane with anti-mouse secondary antibody diluted 1:10,000 in 
wash buffer. 
 Wash the membrane three times for 5 min with wash buffer and then wash 2 times 
with PBS 5 minutes. 
 Incubate with revealer for 1-5 minutes to observe the reaction 
 Stop with PBS. 
 
Blocking buffer: 10% (w/v) non-fat dry milk, 1x PBS, 0.05% Tween-20 
Wash buffer: 1x PBS, 0.05% Tween-20 
Reaveler: 10 mg DAB (3,3′-Diaminobenzidine tetrahydrochloride) in 15 mL of buffer 
(50 mM Tris, 0.15 M NaCl, pH 7.6) 






Annex XII – Protein purification protocol 
 
 
Sample 25 mL sample of the clarified fraction  
Flow rate 5 mL / min 
Binding buffer 
20 mM NaH2PO4 
500 mM NaCl 
6 M urea 
5 mM imidazole 
pH 7.4 
Elution buffer 
20 mM NaH2PO4 
500 mM NaCl 
6 M urea 
500 mM Imidazole 
pH 8.0 
Steps 
1. Balance with 5 CV of binding buffer; 
2. Sample application; 
3. Washing with binding buffer until the 
absorbance at 280 nm reached zero; 
4. Gradient between elution and binding buffer in 
5 CV 
Fractions Not-bounded sample 
Washing samples: 15 mL/fraction 





















Annex XIII – Determination of extracted DNA concentration 
 
Results of absorbance at 260 nm and DNA concentration (µg/mL) calculated for 2 samples 
(P1 and P2) diluted 100 times of DNA extracted from Bordetella pertussis. 
Sample Abs260 (1:100) [DNA] (µg/mL) 
P1  0.732 3660 µg/mL 
P2 0.543 2715 µg/mL 
Average - 3187 µg/mL 
 
Concentration of DNA obtained was determined by the following equation: 
[DNA] (µg/mL) = Abs260 x 50 x FD 
Where: [DNA] is the DNA concentration in µg/mL; Abs260 is the absorbance measured 

























Annex XIV – Image J analysis 
 
Image J software builds a graphic with intensity of all bands present in each fraction of 
the electrophoresis gel. From this graphic, can be selected the peaks and quantified the area of 
each one. The table show values for each band viewed in the gel image. In bold is represented 
the band of the recombinant protein, and the value of this band divided for the sum of all 
fractions gives the percentage of this protein in the sample.  
 
Sample Peak Area Purity 
E2 
1 128485  
2 524335  
3 182556  
4 144192  
5 1719385 54.28% 
6 468556  
Total 3167509  
E3 
1 89071  
2 188607  
3 6225497 71.53% 
4 1153042  
5 751385  
6 296314  
Total 8703916  
E4 
1 5085548 75.21% 
2 236728  
3 1439861  
Total 6762137  
E5 
1 3285355 95.79% 
2 144485  














Annex XV – Results obtained by comparison of the cloned gene sequence with NCBI database  
 
 
 
